Cleo Diagnostics (ASX:COV) Total Assets : A$10.74 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Total Assets?

Cleo Diagnostics's Total Assets for the quarter that ended in Dec. 2023 was A$10.74 Mil.

During the past 12 months, Cleo Diagnostics's average Total Assets Growth Rate was 27.70% per year.

Total Assets is connected with ROA %. Cleo Diagnostics's annualized ROA % for the quarter that ended in Dec. 2023 was -88.39%. Total Assets is also linked to Revenue through Asset Turnover. Cleo Diagnostics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Cleo Diagnostics Total Assets Historical Data

The historical data trend for Cleo Diagnostics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Total Assets Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Total Assets

1.08

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Total Assets	1.30	1.08	10.74

Cleo Diagnostics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Cleo Diagnostics's Total Assets for the fiscal year that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (A: Jun. 2023 )	+	Total Liabilities (A: Jun. 2023 )
	=	-0.943	+	2.02
	=	1.08

Cleo Diagnostics's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	10.54	+	0.199
	=	10.74

Cleo Diagnostics (ASX:COV) Total Assets Explanation

Total Assets is connected with ROA %.

Cleo Diagnostics's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-5.222	/	( (1.077	+	10.739)	/ 2 )
	=	-5.222	/	5.908
	=	-88.39 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Cleo Diagnostics's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (1.077	+	10.739)	/ 2 )
=	0	/	5.908
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Cleo Diagnostics Total Assets Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines